董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dennis Fenton | 男 | Director | 66 | 未披露 | 未持股 | 2017-12-31 |
| Hamza Suria | 男 | President, Chief Executive Officer and Director | 41 | 401.64万美元 | 未持股 | 2017-12-31 |
| Nicholas B. Lydon | 男 | Director | 61 | 26.72万美元 | 未持股 | 2017-12-31 |
| Hollings Renton | 男 | Lead Independent Director | 71 | 未披露 | 未持股 | 2017-12-31 |
| J. Anthony Ware | 男 | Director | 65 | 49.18万美元 | 未持股 | 2017-12-31 |
| Hollings C. Renton | 男 | Lead Independent Director | 70 | 27.82万美元 | 未持股 | 2017-12-31 |
| James N. Topper | 男 | Chairman | 56 | 27.66万美元 | 未持股 | 2017-12-31 |
| John P. Schmid | 男 | Director | 55 | 26.58万美元 | 未持股 | 2017-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Hamza Suria | 男 | President, Chief Executive Officer and Director | 41 | 401.64万美元 | 未持股 | 2017-12-31 |
| Marco Londei | 男 | Chief Medical Officer | 62 | 215.09万美元 | 未持股 | 2017-12-31 |
| Dominic G. Piscitelli | 男 | Chief Financial Officer | 44 | 287.12万美元 | 未持股 | 2017-12-31 |
董事简历
中英对照 | 中文 | 英文- Dennis Fenton
-
Dennis Fenton，他担任我们的董事会成员（2015年2月以来）。从1982年到2008年，他担任Amgen公司（一个生物技术公司）的多种职务。从2000年到2008年，他曾担任执行副总裁，负责操作、制造、过程开发和质量。从1995年到2000年，他曾担任负责业务的高级副总裁。从1992年到1995年，他曾担任公司的高级副总裁，负责销售、营销和开发过程。任职Amgen公司之前，他曾担任Pfizer公司的高级研究科学家，此前曾担任Rutgers University的研究助理和研究生。他目前担任Dendreon Corporation（生物制药公司）、Hospira公司（生物制药公司）、XenoPort公司（生物制药公司）、Kythera Biopharmaceuticals公司（生物制药公司）的董事会成员。在过去的5年里，他曾任职于Genzyme Corporation的董事会。他持有Manhattan College的生物学学士学位，以及美国罗格斯大学（Rutgers University）的微生物学博士学位。
Dennis Fenton, Ph.D., has served as a member of our board of directors since March 2018. From 1981 to 2008 Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company, including Executive Vice President from 2000 until 2008 Senior Vice President of Operations from 1995 until 2000 and Senior Vice President of Sales, Marketing and Process Development from 1992 until 1995. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves on the board of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, and Pfenex Inc. He previously served on the boards of directors of XenoPort, Inc. and Kythera Biopharmaceuticals, Inc., as well as several private company boards. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. - Dennis Fenton，他担任我们的董事会成员（2015年2月以来）。从1982年到2008年，他担任Amgen公司（一个生物技术公司）的多种职务。从2000年到2008年，他曾担任执行副总裁，负责操作、制造、过程开发和质量。从1995年到2000年，他曾担任负责业务的高级副总裁。从1992年到1995年，他曾担任公司的高级副总裁，负责销售、营销和开发过程。任职Amgen公司之前，他曾担任Pfizer公司的高级研究科学家，此前曾担任Rutgers University的研究助理和研究生。他目前担任Dendreon Corporation（生物制药公司）、Hospira公司（生物制药公司）、XenoPort公司（生物制药公司）、Kythera Biopharmaceuticals公司（生物制药公司）的董事会成员。在过去的5年里，他曾任职于Genzyme Corporation的董事会。他持有Manhattan College的生物学学士学位，以及美国罗格斯大学（Rutgers University）的微生物学博士学位。
- Dennis Fenton, Ph.D., has served as a member of our board of directors since March 2018. From 1981 to 2008 Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company, including Executive Vice President from 2000 until 2008 Senior Vice President of Operations from 1995 until 2000 and Senior Vice President of Sales, Marketing and Process Development from 1992 until 1995. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves on the board of directors of Sienna Biopharmaceuticals, Portola Pharmaceuticals, and Pfenex Inc. He previously served on the boards of directors of XenoPort, Inc. and Kythera Biopharmaceuticals, Inc., as well as several private company boards. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University.
- Hamza Suria
-
Hamza Suria，2011年7月以来，他担任我们的总裁和首席执行官，以及我们董事会的成员。从2009年1月到2011年6月，他曾担任副总裁，负责公司发展。2008年12月加入我们公司之前，他曾任职Maxygen公司（生物制药公司），在那里他负责合作和联盟管理肿瘤支持性护理、血液学和自身免疫的下一代蛋白质疗法，包括与医疗和制药公司（如Roche公司、Sanofi公司、Bayer Corporation、Astellas Pharma公司）合作。他持有the University of Western Ontario的免疫学硕士学位、the Richard Ivey School of Business of the University of Western Ontario的执行工商管理硕士学位，以及Kalamazoo College的生物化学学士学位。
Hamza Suria, M.B.A., has served as our President and Chief Executive Officer and a member of our board of directors since July 2011. From January 2009 to June 2011 Mr. Suria served as Vice President of Corporate Development. Before joining our company in December 2008 Mr. Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas Pharma. Mr. Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from Kalamazoo College. - Hamza Suria，2011年7月以来，他担任我们的总裁和首席执行官，以及我们董事会的成员。从2009年1月到2011年6月，他曾担任副总裁，负责公司发展。2008年12月加入我们公司之前，他曾任职Maxygen公司（生物制药公司），在那里他负责合作和联盟管理肿瘤支持性护理、血液学和自身免疫的下一代蛋白质疗法，包括与医疗和制药公司（如Roche公司、Sanofi公司、Bayer Corporation、Astellas Pharma公司）合作。他持有the University of Western Ontario的免疫学硕士学位、the Richard Ivey School of Business of the University of Western Ontario的执行工商管理硕士学位，以及Kalamazoo College的生物化学学士学位。
- Hamza Suria, M.B.A., has served as our President and Chief Executive Officer and a member of our board of directors since July 2011. From January 2009 to June 2011 Mr. Suria served as Vice President of Corporate Development. Before joining our company in December 2008 Mr. Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas Pharma. Mr. Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from Kalamazoo College.
- Nicholas B. Lydon
-
Nicholas B. Lydon，同时我们公司的联席创始人，也曾任职于我们的董事会（2005年11月我们公司创立以来）。他也曾共同创立BluePrint Medicines公司，并任职于公司的董事会（2011年4月以来）。2011年以来，他曾一直担任Staurus Pharma公司（一个生物技术公司）的管理成员。他也是Granite Biopharma公司（咨询公司）的创始人，也曾担任Granite Biopharma 公司的独立成员（2003年以来）。他此前也曾担任Amgen公司的副总裁，负责小分子药物发现（从2000年到2002年）。加入Amgen公司之前，他曾担任Kinetix Pharmaceuticals公司（一个生物科技公司，专注于选择性蛋白激酶抑制剂的发现和开发）的首席执行官兼创始人（从1997年到2000年）。Kinetix Pharmaceuticals公司于2000年被Amgen公司收购。加入Kinetix公司之前，他曾任职CIBA-GEIGY, AG Novartis公司（位于瑞士巴塞尔）（从1985年到1997年），在那里他负责蛋白激酶抑制剂项目，包括伊马替尼格列卫的发现和临床前开发。他的制药生涯始于任职Schering-Plough Corporation（从1982年到1985年），在那里他的研究涉及重组干扰素的研究。他获得了拉斯克-狄贝基临床医学研究奖（the Lasker~DeBakey Clinical Medical Research Award），以及一个日本奖项，因其伊马替尼的工作。他也获得了其它奖项，包括the Warren Alpert Foundation Prize、the AACR Bruce F. Cain Memorial Award、the General Motors Cancer Research Foundation的the Charles F. Kettering Prize。他持有英国利兹大学（The University of Leeds）的生物化学和动物学学士学位，并持有苏格兰邓迪大学医学科学研究所（the Medical Sciences Institute, University of Dundee, Scotland）的生物化学博士学位。
Nicholas B. Lydon, Ph.D., FRS is a co-founder of our company and has served on our board of directors since our company was founded in November 2005. Dr. Lydon also co-founded and has served on the board of directors of BluePrint Medicines Inc. since April 2011. Since 2011 Dr. Lydon has served as Managing Member at Staurus Pharma, LLC, a biotechnology company. Dr. Lydon is also the founder of Granite Biopharma LLC, a consulting company, and has served as sole member of Granite Biopharma since 2003. Dr. Lydon also previously served as Vice President, Small Molecule Drug Discovery at Amgen Inc. from 2000 to 2002. Prior to joining Amgen, he was the Chief Executive Officer and founder of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, from 1997 to 2000. Kinetix Pharmaceuticals was acquired by Amgen in 2000. Prior to joining Kinetix, Dr. Lydon worked at CIBA-GEIGY, AG Novartis in Basel, Switzerland from 1985 to 1997 where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation from 1982 to 1985 where his research involved studies on recombinant interferons. Dr. Lydon has been awarded the Lasker~DeBakey Clinical Medical Research Award and the Japan Prize for his work on Imatinib. Other awards include the Warren Alpert Foundation Prize, the AACR Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation. Dr. Lydon earned his B.S. in Biochemistry and Zoology from the University of Leeds, England, and received his Ph.D. in Biochemistry from the Medical Sciences Institute, University of Dundee, Scotland. - Nicholas B. Lydon，同时我们公司的联席创始人，也曾任职于我们的董事会（2005年11月我们公司创立以来）。他也曾共同创立BluePrint Medicines公司，并任职于公司的董事会（2011年4月以来）。2011年以来，他曾一直担任Staurus Pharma公司（一个生物技术公司）的管理成员。他也是Granite Biopharma公司（咨询公司）的创始人，也曾担任Granite Biopharma 公司的独立成员（2003年以来）。他此前也曾担任Amgen公司的副总裁，负责小分子药物发现（从2000年到2002年）。加入Amgen公司之前，他曾担任Kinetix Pharmaceuticals公司（一个生物科技公司，专注于选择性蛋白激酶抑制剂的发现和开发）的首席执行官兼创始人（从1997年到2000年）。Kinetix Pharmaceuticals公司于2000年被Amgen公司收购。加入Kinetix公司之前，他曾任职CIBA-GEIGY, AG Novartis公司（位于瑞士巴塞尔）（从1985年到1997年），在那里他负责蛋白激酶抑制剂项目，包括伊马替尼格列卫的发现和临床前开发。他的制药生涯始于任职Schering-Plough Corporation（从1982年到1985年），在那里他的研究涉及重组干扰素的研究。他获得了拉斯克-狄贝基临床医学研究奖（the Lasker~DeBakey Clinical Medical Research Award），以及一个日本奖项，因其伊马替尼的工作。他也获得了其它奖项，包括the Warren Alpert Foundation Prize、the AACR Bruce F. Cain Memorial Award、the General Motors Cancer Research Foundation的the Charles F. Kettering Prize。他持有英国利兹大学（The University of Leeds）的生物化学和动物学学士学位，并持有苏格兰邓迪大学医学科学研究所（the Medical Sciences Institute, University of Dundee, Scotland）的生物化学博士学位。
- Nicholas B. Lydon, Ph.D., FRS is a co-founder of our company and has served on our board of directors since our company was founded in November 2005. Dr. Lydon also co-founded and has served on the board of directors of BluePrint Medicines Inc. since April 2011. Since 2011 Dr. Lydon has served as Managing Member at Staurus Pharma, LLC, a biotechnology company. Dr. Lydon is also the founder of Granite Biopharma LLC, a consulting company, and has served as sole member of Granite Biopharma since 2003. Dr. Lydon also previously served as Vice President, Small Molecule Drug Discovery at Amgen Inc. from 2000 to 2002. Prior to joining Amgen, he was the Chief Executive Officer and founder of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, from 1997 to 2000. Kinetix Pharmaceuticals was acquired by Amgen in 2000. Prior to joining Kinetix, Dr. Lydon worked at CIBA-GEIGY, AG Novartis in Basel, Switzerland from 1985 to 1997 where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation from 1982 to 1985 where his research involved studies on recombinant interferons. Dr. Lydon has been awarded the Lasker~DeBakey Clinical Medical Research Award and the Japan Prize for his work on Imatinib. Other awards include the Warren Alpert Foundation Prize, the AACR Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation. Dr. Lydon earned his B.S. in Biochemistry and Zoology from the University of Leeds, England, and received his Ph.D. in Biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.
- Hollings Renton
-
Hollings Renton，他曾担任我们的董事（2015年6月以来）。他此前曾担任Onyx Pharmaceuticals公司的首席执行官兼总裁（从1993年到2008年），也曾担任董事会主席（从2000年到2008年）。加入Onyx Pharmaceuticals公司之前，他曾任职Chiron Corporation（医药公司） ，担任总裁兼首席运营官（从1991年到1993年）。此后，公司收购Cetus Corporation。加入Onyx Pharmaceuticals公司之前，他曾任职Cetus Corporation，担任总裁（从1990年到1991年）、首席运营官（从1987年到1990年），以及首席财务官（从1983年到1987年）。他目前担任多家生命科学公司的董事，包括担任Portola Pharmaceuticals公司的董事会主席，以及Cepheid公司、Kythera Biopharmaceuticals公司的董事会成员。他此前曾任职于Rigel Pharmaceuticals公司、Affymax公司、Sangstat Medical Corporation、Special Olympics Northern California 、the Biotechnology Industry Organization的董事会。他持有the University of Michigan的工商管理硕士学位，以及Colorado State University的数学学士学位。
Hollings Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983 including as President from 1990 to 1991 Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987 prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Mr. Renton served as chair of the board of directors of Portola Pharmaceuticals Inc., where he had been a board member since March 2010 until July 2020. Previously, Mr. Renton served on the boards of three other biopharmaceutical companies, KYTHERA Biopharmaceuticals, Inc. December 2014 to October 2015 Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA. - Hollings Renton，他曾担任我们的董事（2015年6月以来）。他此前曾担任Onyx Pharmaceuticals公司的首席执行官兼总裁（从1993年到2008年），也曾担任董事会主席（从2000年到2008年）。加入Onyx Pharmaceuticals公司之前，他曾任职Chiron Corporation（医药公司） ，担任总裁兼首席运营官（从1991年到1993年）。此后，公司收购Cetus Corporation。加入Onyx Pharmaceuticals公司之前，他曾任职Cetus Corporation，担任总裁（从1990年到1991年）、首席运营官（从1987年到1990年），以及首席财务官（从1983年到1987年）。他目前担任多家生命科学公司的董事，包括担任Portola Pharmaceuticals公司的董事会主席，以及Cepheid公司、Kythera Biopharmaceuticals公司的董事会成员。他此前曾任职于Rigel Pharmaceuticals公司、Affymax公司、Sangstat Medical Corporation、Special Olympics Northern California 、the Biotechnology Industry Organization的董事会。他持有the University of Michigan的工商管理硕士学位，以及Colorado State University的数学学士学位。
- Hollings Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983 including as President from 1990 to 1991 Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987 prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Mr. Renton served as chair of the board of directors of Portola Pharmaceuticals Inc., where he had been a board member since March 2010 until July 2020. Previously, Mr. Renton served on the boards of three other biopharmaceutical companies, KYTHERA Biopharmaceuticals, Inc. December 2014 to October 2015 Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. Mr. Renton is a resident of California, USA.
- J. Anthony Ware
-
J.Anthony Ware，医学博士，自2017年8月起担任我们的董事会成员。2001年至2018年1月，Ware博士在全球制药公司礼来公司担任多个职位，包括2009年10月至2018年1月担任礼来生物医药产品开发高级副总裁，2017年1月至2017年4月担任礼来生物医药临时总裁。在加入礼来公司之前，Ware博士曾担任纽约阿尔伯特·爱因斯坦医学院的医学和分子药理学教授，1996年至2001年，他还担任蒙特菲奥雷医学中心的心脏病学主任。在加入Albert Einstein College of Medicine之前，Ware博士从1984年到1996年在哈佛医学院（Harvard Medical School）任教，并在贝斯以色列医院（Beth Israel Hospital）担任高级医师和冠脉护理单元主任。Ware博士在沃什本大学（Washburn University）获得学士学位，在堪萨斯大学（University of Kansas）获得医学博士学位。他在德克萨斯大学休斯顿分校（University of Texas at Houston）和贝勒医学院（Baylor College of Medicine）完成实习和住院医师，在那里他还担任首席住院医师。他在贝勒大学（Baylor）和哈佛医学院（Harvard Medical School）获得奖学金，并在内科和心血管疾病领域获得董事会认证。
J. Anthony Ware, M.D. has served as a member of our board of directors since August 2017. From 2001 to January 2018 Dr. Ware held numerous positions at Eli Lilly and Company, a global pharmaceutical company, including Senior Vice President of Product Development of Lilly Bio-Medicines from October 2009 to January 2018 and Interim President of Lilly Bio-Medicines from January 2017 to April 2017. Before joining Eli Lilly and Company, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center from 1996 to 2001. Before joining Albert Einstein College of Medicine, Dr. Ware was on the faculty of Harvard Medical School from 1984 to 1996 and served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware received his B.S. from Washburn University, his M.D. from the University of Kansas. He completed internships and residency at The University of Texas at Houston and Baylor College of Medicine, where he also served as Chief Resident. He completed fellowships both at Baylor and at Harvard Medical School, and is board certified both in internal medicine and cardiovascular disease. - J.Anthony Ware，医学博士，自2017年8月起担任我们的董事会成员。2001年至2018年1月，Ware博士在全球制药公司礼来公司担任多个职位，包括2009年10月至2018年1月担任礼来生物医药产品开发高级副总裁，2017年1月至2017年4月担任礼来生物医药临时总裁。在加入礼来公司之前，Ware博士曾担任纽约阿尔伯特·爱因斯坦医学院的医学和分子药理学教授，1996年至2001年，他还担任蒙特菲奥雷医学中心的心脏病学主任。在加入Albert Einstein College of Medicine之前，Ware博士从1984年到1996年在哈佛医学院（Harvard Medical School）任教，并在贝斯以色列医院（Beth Israel Hospital）担任高级医师和冠脉护理单元主任。Ware博士在沃什本大学（Washburn University）获得学士学位，在堪萨斯大学（University of Kansas）获得医学博士学位。他在德克萨斯大学休斯顿分校（University of Texas at Houston）和贝勒医学院（Baylor College of Medicine）完成实习和住院医师，在那里他还担任首席住院医师。他在贝勒大学（Baylor）和哈佛医学院（Harvard Medical School）获得奖学金，并在内科和心血管疾病领域获得董事会认证。
- J. Anthony Ware, M.D. has served as a member of our board of directors since August 2017. From 2001 to January 2018 Dr. Ware held numerous positions at Eli Lilly and Company, a global pharmaceutical company, including Senior Vice President of Product Development of Lilly Bio-Medicines from October 2009 to January 2018 and Interim President of Lilly Bio-Medicines from January 2017 to April 2017. Before joining Eli Lilly and Company, Dr. Ware served as Professor of Medicine and Molecular Pharmacology at Albert Einstein College of Medicine in New York, where he was also Chief of Cardiology at Montefiore Medical Center from 1996 to 2001. Before joining Albert Einstein College of Medicine, Dr. Ware was on the faculty of Harvard Medical School from 1984 to 1996 and served as a senior physician and Director of the Coronary Care Unit at Beth Israel Hospital. Dr. Ware received his B.S. from Washburn University, his M.D. from the University of Kansas. He completed internships and residency at The University of Texas at Houston and Baylor College of Medicine, where he also served as Chief Resident. He completed fellowships both at Baylor and at Harvard Medical School, and is board certified both in internal medicine and cardiovascular disease.
- Hollings C. Renton
-
Hollings C. Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
Hollings C. Renton,has served as a member of Zymeworks Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University. - Hollings C. Renton，自2017年2月起担任Zymeworks Inc.董事会成员。Renton先生于1993年3月至2008年3月担任Onyx Pharmaceuticals，Inc.首席执行官兼总裁，并于2000年6月至2008年3月担任Onyx董事会主席。Onyx于2013年被安进以104亿美元的价格收购。在加入Onyx之前，Renton先生于1991年12月至1993年12月担任制药公司Chiron Corporation的总裁兼首席运营官。Renton先生于1983年在Cetus Corporation担任过多种行政职务，包括1990年至1991年担任总裁、1987年至1990年担任首席运营官以及1983年至1987年担任首席财务官，之后该公司于1991年被Chiron收购。Renton先生自2015年6月起担任AnaptysBio公司董事会成员。此前，Renton先生曾在其他四家生物制药公司的董事会任职，即波尔图制药 Inc.，他还曾担任该公司的董事会主席（2010年3月至2020年7月）、KYTHERA Biopharmaceuticals，Inc.（2014年12月至2015年10月）、Affymax, Inc.（2009年6月至2014年11月）和Rigel Pharmaceuticals, Inc.（2004年1月至2014年3月）。Renton此前还曾在2000年3月至2016年11月期间担任分子诊断公司Cepheid Inc.的董事会成员。Renton先生获得了密西根大学的工商管理硕士学位和科罗拉多州立大学的数学学士学位。
- Hollings C. Renton,has served as a member of Zymeworks Inc. Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies, Portola Pharmaceuticals Inc., where he had also been board chairman (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also previously served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his M.B.A. from the University of Michigan and his B.S. in Mathematics from Colorado State University.
- James N. Topper
-
James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
James N. Topper,was appointed to the Board of Directors in November 2022. Dr. Topper previously served as FLAC's Chief Executive Officer and Chairman of the FLAC Board from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his 15 years as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co-founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co-founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (Nasdaq: ALPN), AnaptysBio, Inc. (Nasdaq: ANAB), Lassen Therapeutics, Seraxis Holdings, Inc., Enlaza Therapeutics, Inc., Serum, Inc. and Sudo Biosciences, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan. - James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
- James N. Topper,was appointed to the Board of Directors in November 2022. Dr. Topper previously served as FLAC's Chief Executive Officer and Chairman of the FLAC Board from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his 15 years as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co-founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co-founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (Nasdaq: ALPN), AnaptysBio, Inc. (Nasdaq: ANAB), Lassen Therapeutics, Seraxis Holdings, Inc., Enlaza Therapeutics, Inc., Serum, Inc. and Sudo Biosciences, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan.
- John P. Schmid
-
John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
John P. Schmid, M.B.A. has served as a member of our board of directors since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co-founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003 and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of Neos Therapeutics, Patara Pharmaceuticals, Xeris Pharmaceuticals and Forge Therapeutics, all pharmaceutical companies, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University. - John P. Schmid，自2015年6月起担任董事；2013年9月至2015年6月间担任Auspex Pharmaceuticals, Inc.的首席财务官。在加入Auspex Pharmaceuticals之前，他联合成立了Trius Therapeutics, Inc.（上市的生物制药公司），并于2004年6月至2013年9月与Cubist Pharmaceuticals, Inc.合并前担任首席财务官。在加入Trius Therapeutics, Inc.之前，他于1998年至2003年和1995年至1998年间分别担任GeneFormatics, Inc.（私营生物技术公司）和Endonetics, Inc.（私营医疗设备公司）的首席财务官。他目前是Neos Therapeutics, Inc.（制药公司）的董事，也是Speak, Inc.（演说家办事处）的董事长，他于1989年联合成立该公司。他获得了the University of San Diego的工商管理硕士学位，以及Wesleyan University的学士学位。
- John P. Schmid, M.B.A. has served as a member of our board of directors since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 to June 2015. Before joining Auspex Pharmaceuticals, Mr. Schmid co-founded Trius Therapeutics, a publicly traded biopharmaceutical company, where he served as the Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc., in September 2013. Before he joined Trius Therapeutics, Mr. Schmid served as the Chief Financial Officer at GeneFormatics, Inc., a private biotechnology company, from 1998 to 2003 and at Endonetics, a private medical device company, from 1995 to 1998. Mr. Schmid currently serves as a member of the board of directors of Neos Therapeutics, Patara Pharmaceuticals, Xeris Pharmaceuticals and Forge Therapeutics, all pharmaceutical companies, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid received his M.B.A. from the University of San Diego and his B.A. from Wesleyan University.
高管简历
中英对照 | 中文 | 英文- Hamza Suria
Hamza Suria，2011年7月以来，他担任我们的总裁和首席执行官，以及我们董事会的成员。从2009年1月到2011年6月，他曾担任副总裁，负责公司发展。2008年12月加入我们公司之前，他曾任职Maxygen公司（生物制药公司），在那里他负责合作和联盟管理肿瘤支持性护理、血液学和自身免疫的下一代蛋白质疗法，包括与医疗和制药公司（如Roche公司、Sanofi公司、Bayer Corporation、Astellas Pharma公司）合作。他持有the University of Western Ontario的免疫学硕士学位、the Richard Ivey School of Business of the University of Western Ontario的执行工商管理硕士学位，以及Kalamazoo College的生物化学学士学位。
Hamza Suria, M.B.A., has served as our President and Chief Executive Officer and a member of our board of directors since July 2011. From January 2009 to June 2011 Mr. Suria served as Vice President of Corporate Development. Before joining our company in December 2008 Mr. Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas Pharma. Mr. Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from Kalamazoo College.- Hamza Suria，2011年7月以来，他担任我们的总裁和首席执行官，以及我们董事会的成员。从2009年1月到2011年6月，他曾担任副总裁，负责公司发展。2008年12月加入我们公司之前，他曾任职Maxygen公司（生物制药公司），在那里他负责合作和联盟管理肿瘤支持性护理、血液学和自身免疫的下一代蛋白质疗法，包括与医疗和制药公司（如Roche公司、Sanofi公司、Bayer Corporation、Astellas Pharma公司）合作。他持有the University of Western Ontario的免疫学硕士学位、the Richard Ivey School of Business of the University of Western Ontario的执行工商管理硕士学位，以及Kalamazoo College的生物化学学士学位。
- Hamza Suria, M.B.A., has served as our President and Chief Executive Officer and a member of our board of directors since July 2011. From January 2009 to June 2011 Mr. Suria served as Vice President of Corporate Development. Before joining our company in December 2008 Mr. Suria worked at Maxygen, Inc., a biopharmaceutical company, where he was responsible for partnering and alliance management of next-generation protein therapeutics in oncology supportive care, hematology and autoimmunity, including partnerships with healthcare and pharmaceutical companies, such as Roche, Sanofi S.A., Bayer Corporation and Astellas Pharma. Mr. Suria received his M.S. in immunology from the University of Western Ontario, his Executive M.B.A. from the Richard Ivey School of Business of the University of Western Ontario and his B.S. in biochemistry from Kalamazoo College.
- Marco Londei
Marco Londei，2014年10月以来，他一直担任我们的首席开发官。加入我们公司之前，他曾担任Bristol-Myers Squibb公司（生物制药公司）的Immunosciences治疗区域负责人（从2012年11月到2014年9月）。开始任职Bristol-Myers Squibb公司之前，他曾担任Novartis公司的自身免疫、移植和炎症部门的转化医学全球主管，以及the Genomics Institute of the Novartis Research Foundation的转化科学官（从2005年10月到2012年10月）。他曾担任肯尼迪风湿病学研究所（the Kennedy Institute of Rheumatology）、伦敦帝国理工学院医学院（Imperial College School of Medicine, London）的教授（从1999年7月到2003年7月），后也曾担任英国伦敦大学医学院（University College London, Medical School UK）的教授和胃肠病学主管（从2003年7月到2007年9月）。他持有Università di Bologna的医学博士学位。
Marco Londei, M.D. has served as our Chief Medical Officer since October 2016. Prior to that, Dr. Londei served as our Chief Development Officer since October 2014. Before joining our company, Dr. Londei worked as Therapeutic Area Head Immunosciences, at Bristol-Myers Squibb, a biopharmaceutical company, from November 2012 to September 2014. Before starting at Bristol-Myers Squibb, Dr. Londei served as Global Head Translational Medicine of the Autoimmunity, Transplantation & Inflammation Department at Novartis AG and Translational Science Officer at the Genomics Institute of the Novartis Research Foundation from October 2005 to October 2012. Dr. Londei was Professor at the Kennedy Institute of Rheumatology, Imperial College School of Medicine, London, from July 1999 to July 2003 and then Professor and head of the gastroenterology unit at University College London, Medical School UK, from July 2003 through September 2007. Dr. Londei received his M.D. from Università di Bologna.- Marco Londei，2014年10月以来，他一直担任我们的首席开发官。加入我们公司之前，他曾担任Bristol-Myers Squibb公司（生物制药公司）的Immunosciences治疗区域负责人（从2012年11月到2014年9月）。开始任职Bristol-Myers Squibb公司之前，他曾担任Novartis公司的自身免疫、移植和炎症部门的转化医学全球主管，以及the Genomics Institute of the Novartis Research Foundation的转化科学官（从2005年10月到2012年10月）。他曾担任肯尼迪风湿病学研究所（the Kennedy Institute of Rheumatology）、伦敦帝国理工学院医学院（Imperial College School of Medicine, London）的教授（从1999年7月到2003年7月），后也曾担任英国伦敦大学医学院（University College London, Medical School UK）的教授和胃肠病学主管（从2003年7月到2007年9月）。他持有Università di Bologna的医学博士学位。
- Marco Londei, M.D. has served as our Chief Medical Officer since October 2016. Prior to that, Dr. Londei served as our Chief Development Officer since October 2014. Before joining our company, Dr. Londei worked as Therapeutic Area Head Immunosciences, at Bristol-Myers Squibb, a biopharmaceutical company, from November 2012 to September 2014. Before starting at Bristol-Myers Squibb, Dr. Londei served as Global Head Translational Medicine of the Autoimmunity, Transplantation & Inflammation Department at Novartis AG and Translational Science Officer at the Genomics Institute of the Novartis Research Foundation from October 2005 to October 2012. Dr. Londei was Professor at the Kennedy Institute of Rheumatology, Imperial College School of Medicine, London, from July 1999 to July 2003 and then Professor and head of the gastroenterology unit at University College London, Medical School UK, from July 2003 through September 2007. Dr. Londei received his M.D. from Università di Bologna.
- Dominic G. Piscitelli
Dominic G. Piscitelli， 他曾一直担任我们的首席财务官（2017年1月以来）。他拥有15年以上的制药和生物制药行业经验，以及20年以上的财务经验。加入我们之前，他曾担任Medivation, Inc.（生物制药公司）的财务副总裁（从2012年9月到2017年1月）。此前，他曾担任Astellas Pharma US, Inc.（生物制药公司）的全球财务高级主管（从2011年1月到2012年9月）。2001年9月至2011年1月，他曾任职OSI Pharmaceuticals, Inc（一个生物科技公司，于2010年6月被Astellas Pharma US, Inc.收购），担任财政部和金融管理副总裁（2009年至2011年），此前曾担任负责肿瘤学财务与财务的高级主管、商业财务主管、助理主管兼助理总会计师，负责证券交易委员会报告。他持有Hofstra University的工商管理学士学位和工商管理硕士学位。
Dominic G. Piscitelli, M.B.A., C.P.A., commenced serving as our Chief Financial Officer in January 2017. Before joining us, from September 2012 to January 2017 Mr. Piscitelli served as the Vice President of Finance at Medivation, Inc., a biopharmaceutical company. Prior to that, from January 2011 to September 2012 Mr. Piscitelli served as the Senior Director of Global Finance at Astellas Pharma US, Inc., a pharmaceutical company. From September 2001 to January 2011 Mr. Piscitelli held positions at OSI Pharmaceuticals, Inc., a biotechnology company that was acquired by Astellas Pharma US, Inc. in June 2010 serving as the Vice President of Treasury and Management Finance from 2009 to 2011 and previously as Senior Director, Oncology Finance & Treasury, Director, Commercial Finance and Associate Director/Assistant Controller, SEC Reporting. Mr. Piscitelli earned both his B.A. in Business Administration and his M.B.A. from Hofstra University.- Dominic G. Piscitelli， 他曾一直担任我们的首席财务官（2017年1月以来）。他拥有15年以上的制药和生物制药行业经验，以及20年以上的财务经验。加入我们之前，他曾担任Medivation, Inc.（生物制药公司）的财务副总裁（从2012年9月到2017年1月）。此前，他曾担任Astellas Pharma US, Inc.（生物制药公司）的全球财务高级主管（从2011年1月到2012年9月）。2001年9月至2011年1月，他曾任职OSI Pharmaceuticals, Inc（一个生物科技公司，于2010年6月被Astellas Pharma US, Inc.收购），担任财政部和金融管理副总裁（2009年至2011年），此前曾担任负责肿瘤学财务与财务的高级主管、商业财务主管、助理主管兼助理总会计师，负责证券交易委员会报告。他持有Hofstra University的工商管理学士学位和工商管理硕士学位。
- Dominic G. Piscitelli, M.B.A., C.P.A., commenced serving as our Chief Financial Officer in January 2017. Before joining us, from September 2012 to January 2017 Mr. Piscitelli served as the Vice President of Finance at Medivation, Inc., a biopharmaceutical company. Prior to that, from January 2011 to September 2012 Mr. Piscitelli served as the Senior Director of Global Finance at Astellas Pharma US, Inc., a pharmaceutical company. From September 2001 to January 2011 Mr. Piscitelli held positions at OSI Pharmaceuticals, Inc., a biotechnology company that was acquired by Astellas Pharma US, Inc. in June 2010 serving as the Vice President of Treasury and Management Finance from 2009 to 2011 and previously as Senior Director, Oncology Finance & Treasury, Director, Commercial Finance and Associate Director/Assistant Controller, SEC Reporting. Mr. Piscitelli earned both his B.A. in Business Administration and his M.B.A. from Hofstra University.